Merus (MRUS)
(Delayed Data from NSDQ)
$57.30 USD
+3.30 (6.11%)
Updated May 30, 2024 04:00 PM ET
After-Market: $57.85 +0.55 (0.96%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Merus N.V. (MRUS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$63.18 | $90.00 | $44.00 | 17.00% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Merus N.V. comes to $63.18. The forecasts range from a low of $44.00 to a high of $90.00. The average price target represents an increase of 17% from the last closing price of $54.00.
Analyst Price Targets (11)
Broker Rating
Merus N.V. currently has an average brokerage recommendation (ABR) of 1.08 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.08 a month ago based on 13 recommendations.
Of the 12 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 91.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 92.31%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 12 | 12 | 12 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/28/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
5/24/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
5/8/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
4/22/2024 | William Blair | Matt Phipps | Strong Buy | Strong Buy |
3/4/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
2/29/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
2/29/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
11/2/2023 | Canaccord Genuity | William Maughan | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.08 |
ABR (Last week) | 1.08 |
# of Recs in ABR | 12 |
Average Target Price | $63.18 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | -0.77 |